🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
1.240
-0.090 (-6.77%)
At close: Nov 20, 2026, 4:00 PM EST
1.249
+0.009 (0.71%)
After-hours: Nov 20, 2026, 7:34 PM EST

Seres Therapeutics Stock Forecast

MCRB's stock price has decreased by -95.67% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 2 analysts polled by S&P Global, Seres Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $17. The average 1-year stock price forecast is 1,270.97% higher than the current stock price, while the lowest is $12 (+867.74%) and the highest is $22 (+1,674.19%).

Price Target: $17 (+1,270.97%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$12$17$17$22
Change+867.74%+1271.0%+1271.0%+1674.2%

Analyst Ratings

The average analyst rating for Seres Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26May '26Jun '26Jul '26Aug '26Nov '26
Strong Buy112222
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total112222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$22
BuyMaintains$22+1,674.19%Nov 5, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$12
BuyReiterates$12+867.74%Nov 4, 2026

Financial Forecast

Revenue This Year
13.80M
from 789.00K
Increased by 1,648.67%
Revenue Next Year
273.50K
from 13.80M
Decreased by -98.02%
EPS This Year
-3.52
from 0.64
EPS Next Year
-4.95
from -3.52
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
144.93M---789.00K13.80M
Revenue Growth
336.33%----1,648.67%
Operating Income
-64.49M-179.91M-195.10M-121.32M-93.97M-66.09M
Net Income
-65.58M-250.16M-113.72M136.00K5.70M-37.49M
EPS
----0.64-3.52
Free Cash Flow
------5.00M
No. Analysts
-----2
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High26.1M
Avg13.8M
Low1.5M

Revenue Growth

Revenue Growth202620272028
High
3,207.2%
Avg
1,648.7%
Low
90.1%

EPS Forecast

EPS202620272028
High-2.67
Avg-3.52
Low-4.36

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-